That so few patients were subsequently prescribed GLP-1 RA following incident stroke in the present study (6.6%) likely reflects the lack of recommendations for the use of these treatments to prevent cardiovascular disease in most of the years covered by this study [6]. The gene discussed is GLP1R; the disease is stroke disorder.